Substance use, medication adherence and outcome one year following a first episode of psychosis

Schizophrenia Research

Volumn 170, Issue 2-3, 2016, Pages 311-317

  Colizzi, Marco ^a   Carra, Elena ^a   Fraietta, Sara ^a   Lally, John ^a   Quattrone, Diego ^a   Bonaccorso, Stefania ^a   Mondelli, Valeria ^a   Ajnakina, Olesya ^a   Dazzan, Paola ^a   Trotta, Antonella ^a   Sideli, Lucia ^a   Kolliakou, Anna ^b   Gaughran, Fiona ^a   Khondoker, Mizanur ^a   David, Anthony S ^a   Murray, Robin M ^a   MacCabe, James H ^a   Di Forti, Marta ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b King's College London   (United Kingdom)

Author keywords

Cannabis use; First episode psychosis; Medication adherence; Nicotine dependence; Remission; Substance use

Indexed keywords

ALCOHOL; CANNABIS; CENTRAL STIMULANT AGENT; NEUROLEPTIC AGENT;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; CANNABIS USE; CONTROLLED STUDY; DISEASE COURSE; DRUG DEPENDENCE; DRUG USE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PREDICTION; PRIORITY JOURNAL; PSYCHOSIS; REMISSION; SUBSTANCE USE; TOBACCO; ACUTE DISEASE; COMPLICATION; MEDICATION COMPLIANCE; MIDDLE AGED; PSYCHOTIC DISORDERS; TREATMENT OUTCOME; YOUNG ADULT;

ACUTE DISEASE; ADULT; ANTIPSYCHOTIC AGENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PSYCHOTIC DISORDERS; SUBSTANCE-RELATED DISORDERS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84958847298     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2015.11.016     Document Type: Article

References (46)

1. Addington J., Addington D. Patterns, predictors and impact of substance use in early psychosis: a longitudinal study. Acta Psychiatr. Scand. 2007, 115(4):304-309.
2. Agrawal A., Budney A.J., Lynskey M.T. The co-occurring use and misuse of cannabis and tobacco: a review. Addiction 2012, 107(7):1221-1233.
3. Alvarez-Jimenez M., Priede A., Hetrick S.E., Bendall S., Killackey E., Parker A.G., McGorry P.D., Gleeson J.F. Risk factors for relapse following treatment for first episode psychosis: a systematic review and meta-analysis of longitudinal studies. Schizophr. Res. 2012, 139(1-3):116-128.
4. Atakan Z. Cannabis use by people with severe mental illness - is it important?. Adv. Psychiatr. Treat. 2008, 14:423-431.
5. Babor T., De La Fuente J.R., Saunders J.B., Grant M. AUDIT - The Alcohol Use Disorders Identification Test: Guidelines for Use in Primary Health Care 1989, World Health Organization.
6. Baron R.M., Kenny D.A. The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations. J. Pers. Soc. Psychol. 1986, 51:1173-1182.
7. Bloomfield M.A., Morgan C.J., Egerton A., Kapur S., Curran H.V., Howes O.D. Dopaminergic function in cannabis users and its relationship to cannabis-induced psychotic symptoms. Biol. Psychiatry 2014, 75(6):470-478.
8. Brody A.L., London E.D., Olmstead R.E., Allen-Martinez Z., Shulenberger S., Costello M.R., Abrams A.L., Scheibal D., Farahi J., Shoptaw S., Mandelkern M.A. Smoking-induced change in intrasynaptic dopamine concentration: effect of treatment for tobacco dependence. Psychiatry Res. 2010, 183(3):218-224.
9. Caseiro O., Perez-Iglesias R., Mata I., Martinez-Garcia O., Pelayo-Teran J.M., Tabares-Seisdedos R., Ortiz-García dela Foz V., Vázquez-Barquero J.L., Crespo-Facorro B. Predicting relapse after a first episode of non-affective psychosis: a three-year follow-up study. J Psychiatr. Res. 2012, 46(8):1099-1105.
10. Cassidy C.M., Schmitz N., Malla A. Validation of the alcohol use disorders identification test and the drug abuse screening test in first episode psychosis. Can. J. Psychiatr. 2008, 53(1):26-33.
11. Coldham E.L., Addington J., Addington D. Medication adherence of individuals with a first-episode of psychosis. Acta Psychiatr. Scand. 2002, 106:286-290.
12. Colizzi M., Iyegbe C., Powell J., Blasi G., Bertolino A., Murray R.M., Di Forti M. Interaction between DRD2 and AKT1 genetic variations on risk of psychosis in cannabis users: a case-control study. NPJ Schizophr. 2015, 1:15025.
13. Colizzi M., Iyegbe C., Powell J., Ursini G., Porcelli A., Bonvino A., Taurisano P., Romano R., Masellis R., Blasi G., Morgan C., Aitchison K., Mondelli V., Luzi S., Kolliakou A., David A., Murray R.M., Bertolino A., Di Forti M. Interaction between functional genetic variation of DRD2 and cannabis use on risk of psychosis. Schizophr. Bull. 2015, 41(5):1171-1182.
14. Cotton S.M., Lambert M., Schimmelmann B.G., Foley D.L., Morley K.I., McGorry P.D., Conus P. Gender differences in premorbid, entry, treatment, and outcome characteristics in a treated epidemiological sample of 661 patients with first episode psychosis. Schizophr. Res. 2009, 114(1-3):17-24.
15. Depp C.A., Bowie C.R., Mausbach B.T., Wolyniec P., Thornquist M.H., Luke J.R., McGrath J.A., Pulver A.E., Patterson T.L., Harvey P.D. Current smoking is associated with worse cognitive and adaptive functioning in serious mental illness. Acta Psychiatr. Scand. 2015, 131(5):333-341.
16. Di Forti M., Morgan C., Dazzan P., Pariante C., Mondelli V., Marques T.R., Handley R., Luzi S., Russo M., Paparelli A., Butt A., Stilo S.A., Wiffen B., Powell J., Murray R.M. High-potency cannabis and the risk of psychosis. Br. J. Psychiatry 2009, 195(6):488-491.
17. Di Forti M., Iyegbe C., Sallis H., Kolliakou A., Falcone M.A., Paparelli A., Sirianni M., La Cascia C., Stilo S.A., Marques T.R., Handley R., Mondelli V., Dazzan P., Pariante C., David A.S., Morgan C., Powell J., Murray R.M. Confirmation that the AKT1 (rs2494732) genotype influences the risk of psychosis in cannabis users. Biol. Psychiatry 2012, 72(10):811-816.
18. Dixon L. Dual diagnosis of substance abuse in schizophrenia: prevalence and impact on outcomes. Schizophr. Res. 1999, 35:93-100.
19. Faridi K., Joober R., Malla A. Medication adherence mediates the impact of sustained cannabis use on symptom levels in first-episode psychosis. Schizophr. Res. 2012, 141(1):78-82.
20. Gray R., Wykes T., Gournay K. From compliance to concordance: a review of the literature on interventions to enhance compliance with antipsychotic medication. J. Psychiatr. Ment. HLT. 2002, 9(3):277-284.
21. Gurillo P., Jauhar S., Murray R.M., MacCabe J.H. Does tobacco use cause psychosis? Systematic review and meta-analysis. Lancet Psychiatry 2015, 2(8):718-725.
22. Heatherton T.F., Kozlowski L.T., Frecker R.C., Fagerström K.O. The Fagerström test for nicotine dependence: a revision of the fagerström tolerance questionnaire. Br. J. Addict. 1991, 86(9):1119-1127.
23. Hill M., Crumlish N., Whitty P., Clarke M., Browne S., Kamali M., Kinsella A., Waddington J.L., Larkin C., O'Callaghan E. Nonadherence to medication four years after a first episode of psychosis and associated risk factors. Psychiatr. Serv. 2010, 61(2):189-192.
24. Janca A., Chandrashekar C.R. Catalogue of World Health Organization (WHO) Psychiatric Assessment Instruments 1995, World Health Organization.
25. Kahn R.S., Fleischhacker W.W., Boter H., Davidson M., Vergouwe Y., Keet I.P., Gheorghe M.D., Rybakowski J.K., Galderisi S., Libiger J., Hummer M., Dollfus S., López-Ibor J.J., Hranov L.G., Gaebel W., Peuskens J., Lindefors N., Riecher-Rössler A., Grobbee D.E., EUFEST study group Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 2008, 371:1085-1097.
26. King D., Knapp M., Patel A., Amaddeo F., Tansella M., Schene A., Angermeyer M., Becker T. The impact of non-adherence to medication in patients with schizophrenia on health, social care and societal costs. Analysis of the QUATRO study. Epidemiol. Psychiatr. Sci. 2014, 23(01):61-70.
27. Krishnadas R., Jauhar S., Telfer S., Shivashankar S., McCreadie R.G. Nicotine dependence and illness severity in schizophrenia. Br. J. Psychiatry 2012, 201(4):306-312.
28. Lambert M., Conus P., Cotton S., Robinson J., McGorry P.D., Schimmelmann B.G. Prevalence, predictors, and consequences of long-term refusal of antipsychotic treatment in first-episode psychosis. J. Clin. Psychopharmacol. 2010, 30:565-572.
29. Levy E., Pawliuk N., Joober R., Abadi S., Malla A. Medication-adherent first-episode psychosis patients also relapse: why?. Can. J. Psychiatr. 2012, 57(2):78-84.
30. Malla A., Norman R., Schmitz N., Manchanda R., Béchard-Evans L., Takhar J., Haricharan R. Predictors of rate and time to remission in first episode psychosis: a two-year outcome study. Psychol. Med. 2006, 36:649-658.
31. Mallett R., Leff J., Bhugra D., Pang D., Zhao J.H. Social environment, ethnicity and schizophrenia. A case-control study. Soc. Psychiatry Psychiatr. Epidemiol. 2002, 37:329-335.
32. McGuffin P., Farmer A., Harvey I. A polydiagnostic application of operational criteria in studies of psychotic illness. Development and reliability of the OPCRIT system. Arch. Gen. Psychiatry 1991, 48(8):764-770.
33. Miller R., Ream G., McCormack J., Gunduz-Bruce H., Sevy S., Robinson D. A prospective study of cannabis use as a risk factor for non-adherence and treatment dropout in first-episode schizophrenia. Schizophr. Res. 2009, 113(2-3):138-144.
34. Miller B.J., Bodenheimer C., Crittenden K. Second-generation antipsychotic discontinuation in first episode psychosis: an updated review. Clin. Psychopharmacol. Neurosci. 2011, 9(2):45-53.
35. Murray R.M., Mehta M., Di Forti M. Different dopaminergic abnormalities underlie cannabis dependence and cannabis-induced psychosis. Biol. Psychiatry 2014, 75(6):430-431.
36. Myles, N., Newall, H.D., Curtis, J., Nielssen, O., Shiers, D., Large, M., 2012. Tobacco use before, at, and after first-episode psychosis: a systematic meta-analysis. J. Clin. Psychiatry 73 (4) 468-475.
37. Novak-Grubic V., Tavcar R. Predictors of noncompliance in males with first-episode schizophrenia, schizophreniform and schizoaffective disorder. Eur. Psychol. 2002, 17:148-154.
38. Park A., McCrone P., Knapp M. Early intervention for first-episode psychosis: broadening the scope of economic estimates. Early Interv. Psychiatry. 2014, 10.1111/eip.12149.
39. Perkins D.O., Gu H., Weiden P.J., McEvoy J.P., Hamer R.M., Lieberman J.A. Comparison of atypicals in first episode study group. Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study. J. Clin. Psychiatry. 2008, 69(1):106-113.
40. Sobel M.E., Leinhardt S. In Asymptotic Confidence Intervals for Indirect Effects in Structural Equation Models 1982, 290-312. American Sociological Association, Washington DC.
41. Van Mastrigt S., Addington J., Addington D. Substance misuse at presentation to an early psychosis program. Soc. Psychiatry Psychiatr. Epidemiol. 2004, 39(1):69-72.
42. Verdoux H., Lengronne J., Liraud F., Gonzales B., Assens F., Abalan F., van Os J. Medication adherence in psychosis: predictors and impact on outcome. A 2-year follow-up of first-admitted subjects. Acta Psychiatr. Scand. 2000, 102:203-210.
43. Wade D., Harrigan S., McGorry P.D., Burgess P.M., Whelan G. Impact of severity of substance use disorder on symptomatic and functional outcome in young individuals with first-episode psychosis. J. Clin. Psychiatry 2007, 68(5):767-774.
44. World Health Organization Schedules for Clinical Assessment in Neuropsychiatry (SCAN) 1992, World Health Organization.
45. Zammit S., Moore T.H., Lingford-Hughes A., Barnes T.R., Jones P.B., Burke M., Lewis G. Effects of cannabis use on outcomes of psychotic disorders: systematic review. Br. J. Psychiatry 2008, 193(5):357-363.
46. Zvolensky M.J., Taha F., Bono A., Goodwin R.D. Big five personality factors and cigarette smoking: a 10-year study among US adults. J. Psychiatr. Res. 2015, 63:91-96.